- Home
- PLRX vs ORIC Comparison
PLRX vs ORIC Comparison
Compare PLRX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- ORIC
- Stock Information
- Founded
- PLRX 2015
- ORIC 2014
- Country
- PLRX United States
- ORIC United States
- Employees
- PLRX N/A
- ORIC N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- ORIC Health Care
- Exchange
- PLRX Nasdaq
- ORIC Nasdaq
- Market Cap
- PLRX 89.0M
- ORIC 974.1M
- IPO Year
- PLRX 2020
- ORIC 2020
- Fundamental
- Price
- PLRX $1.53
- ORIC $10.71
- Analyst Decision
- PLRX Hold
- ORIC Strong Buy
- Analyst Count
- PLRX 10
- ORIC 10
- Target Price
- PLRX $3.93
- ORIC $17.33
- AVG Volume (30 Days)
- PLRX 725.5K
- ORIC 886.3K
- Earning Date
- PLRX 11-06-2025
- ORIC 11-11-2025
- Dividend Yield
- PLRX N/A
- ORIC N/A
- EPS Growth
- PLRX N/A
- ORIC N/A
- EPS
- PLRX N/A
- ORIC N/A
- Revenue
- PLRX N/A
- ORIC N/A
- Revenue This Year
- PLRX N/A
- ORIC N/A
- Revenue Next Year
- PLRX N/A
- ORIC N/A
- P/E Ratio
- PLRX N/A
- ORIC N/A
- Revenue Growth
- PLRX N/A
- ORIC N/A
- 52 Week Low
- PLRX $1.10
- ORIC $3.90
- 52 Week High
- PLRX $16.10
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- PLRX 44.68
- ORIC 55.85
- Support Level
- PLRX $1.66
- ORIC $10.36
- Resistance Level
- PLRX $1.85
- ORIC $11.20
- Average True Range (ATR)
- PLRX 0.13
- ORIC 0.49
- MACD
- PLRX -0.02
- ORIC 0.06
- Stochastic Oscillator
- PLRX 12.20
- ORIC 67.35
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.